Search clinical trials for: BMS-986278 Placebo

Total 56631 results

Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Healthy Participants | Idiopathic Pulmonary Fibrosis (IPF)

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Melanoma

Spain, United States, Italy, Chile, Greece, Argentina
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 in Healthy Participants

Healthy

Belgium
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Melanoma | Skin Cancer

United States, Canada, Netherlands, Spain, Australia, Italy, Japan, Germany, Ireland, United Kingdom, Czechia, Switzerland, Poland, France, Greece, New Zealand
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants

Healthy

China
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Bristol-Myers Squibb

Completed

A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants

Healthy Volunteers

United Kingdom
M.D. Anderson Cancer Center

Active, not recruiting

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Malignant... and other conditions

United States
Bristol-Myers Squibb

Completed

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Healthy

United States
Bristol-Myers Squibb

Completed

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (ADVISE)

Advanced Cancer

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Heart Failure
MedSIR
Medical University of Vienna

Not yet recruiting

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (REPOSE)

NSCLC | Brain Metastases | ROS1 Gene Rearrangement
Celgene

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

Healthy Volunteers

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Gastric Adenocarcinoma | Esophagogastric Cancer | Gastroesophageal Junction Adenocarcinoma | Esophagus Cancer | Gastroesophageal Junction Squamous Cell Carcinoma

United States
Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Renal Impairment

United States
Ronald Levy
National Cancer Institute (NCI)

Active, not recruiting

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | B-Cell Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Myelofibrosis

Italy, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
Bristol-Myers Squibb

Active, not recruiting

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

Cardiomyopathy, Hypertrophic

Spain, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Israel, Japan, Netherlands, Norway, Poland, Portugal, United Kingdom, United States, Australia, China, Czechia, India, Italy, Korea, Republic of
LianBio LLC

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Obstructive Hypertrophic Cardiomyopathy

China
Bristol-Myers Squibb

Completed

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

Congestive Heart Failure | Liver Dysfunction | Heart Decompensation | Cardiac Failure | Liver Insufficiency | Myocardial Failure | Hepatic Failure

Hungary, Poland
Bristol-Myers Squibb

Recruiting

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Healthy Volunteers | Hepatic Impairment

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet

Healthy Volunteers

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors (RELATIVITY 059)

Advanced Solid Tumors

China
Bristol-Myers Squibb

Completed

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

Heart Failure | Cardiac Failure | Reduced Ventricular Ejection Fraction

United States, United Kingdom, Japan, Netherlands
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Completed

Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

Thrombosis

United States
Thomas Jefferson University
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Larynx | Squamous Cell Carcinoma | Lip | Oral Cavity Squamous Cell Carcinoma | Pharynx

United States
Bristol-Myers Squibb

Completed

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Belgium, Germany, Israel, Poland, Spain, Turkey, Australia, Chile, France
Biogen

Terminated

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)

Alzheimer's Disease

United States, Spain, Italy, Australia, France, Poland, Germany, Japan, Sweden
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Melanoma | Cancer

United States, Poland, Italy, Belgium, France, Australia, Canada, Germany, Spain, Sweden, Switzerland, United Kingdom
Bristol-Myers Squibb

Terminated

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

Cancer

Canada, United States
Bristol-Myers Squibb

Active, not recruiting

An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Advanced Cancer

France, United States, Spain, Canada, Argentina, Chile, Italy
Bristol-Myers Squibb

Active, not recruiting

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy (HORIZON-HCM)

Cardiomyopathy, Hypertrophic Obstructive

Japan
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Advanced Cancer

United States, Australia, Canada, Japan
Bristol-Myers Squibb

Completed

A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection (CheckMate-6GE)

Melanoma

United States, Australia, Belgium, Italy, Poland, Spain, United Kingdom
Bristol-Myers Squibb

Withdrawn

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Melanoma | Urothelial Carcinoma

Germany, Spain
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

Heart Failure

United States
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
Bristol-Myers Squibb

Completed

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

Healthy Participants

United States
Northwestern University
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Neoplasms by Site

United States, Mexico, Italy, Argentina, Brazil, Chile, France, Netherlands, New Zealand, Poland, Spain, United Kingdom
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)

Bulgaria, United States
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Advanced Cancer

Italy, Australia, United States, Spain, Romania, Argentina, Canada, Chile, Finland, Germany, Poland
Bristol-Myers Squibb

Terminated

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Advanced Cancer

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Broad Solid Tumor

United States, Argentina, Australia, Canada, Chile, Japan, Romania, Singapore

Search clinical trials for: BMS-986278 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations